Abstract
Background
Ewing sarcoma, a malignancy originating from the bone or soft tissues most commonly
diagnosed in adolescents, requires multimodality therapy. Although both surgical resection
and radiation therapy are effective local control modalities, there are limited data
comparing outcomes in patients treated with surgery versus radiation. We sought to
determine whether there were differences in 5-year local failure-free survival, event-free
survival, and overall survival based on the modality used for local control.
Methods
Patients treated for Ewing sarcoma at a single tertiary pediatric hospital between
2010 and 2020 were included for retrospective analysis. Patient and tumor demographics,
treatment information, and patient response to therapies were collected from the medical
record. Outcome measures were local failure-free survival, event-free survival, and
overall survival at 5 years from diagnosis.
Results
Sixty-one patients met inclusion criteria. All patients received chemotherapy, and
68.9% of patients presented with localized disease. Of these, 23.8% were treated with
radiation alone; the remaining 76.2% underwent resection ± radiation. A total of 52.4%
of patients with localized disease achieved R0 resection. Only 3 patients experienced
local progression; there was no difference between treatment groups. There was no
significant association between local control modality and event-free survival or
overall survival in patients with localized disease, regardless of margin status.
Conclusion
There was no significant difference in 5-year local failure-free survival, event-free
survival, or overall survival in Ewing sarcoma patients treated with radiation versus
surgery ± radiation, regardless of whether or not R0 resection was achieved. Future
directions include a multi-institutional study to allow for further subgroup analysis
and increased sample size.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Declining childhood and adolescent cancer mortality.Cancer. 2014; 120: 2497-2506
- Survival Rates for Ewing Tumors.https://www.cancer.org/cancer/ewing-tumor/detection-diagnosis-staging/survival-rates.html(Updated May 25, 2021)Date: 2021Date accessed: February 18, 2022
- Should aggressive surgical local control be attempted in all patients with metastatic or pelvic Ewing’s sarcoma?.Sarcoma. 2012; 2012953602
- Does surgery or radiation provide the best overall survival in Ewing's sarcoma? A review of the National Cancer Data Base.J Surg Oncol. 2017; 116: 384-390
- Local control in pelvic Ewing sarcoma: analysis from INT-0091—a report from the Children’s Oncology Group.J Clin Oncol. 2006; 24: 3838-3843
- A systematic review of optimal treatment strategies for localized Ewing’s sarcoma of bone after neo-adjuvant chemotherapy.Surg Oncol. 2016; 25: 16-23
- Current status of management and outcome for patients with Ewing sarcoma.Cancers (Basel). 2021; 13
American Cancer Society. Radiation Therapy Side Effects. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/effects-on-different-parts-of-body.html. Updated December 10, 2020. Accessed February 18, 2022.
- Ewing’s sarcoma of the femur: prognosis in 69 patients treated by the CESS group.Acta Orthop Scand. 1997; 68: 20-24
- Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children’s Oncology Group.Cancer. 2015; 121: 467-475
- Local and systemic control in Ewing’s sarcoma of the femur treated with chemotherapy, and locally by radiotherapy and/or surgery.J Bone Joint Surg Br. 2003; 85: 107-114
- The role of surgical margins in treatment of Ewing’s sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy.Int J Radiat Oncol Biol Phys. 2006; 65: 766-772
- Nonmetastatic pelvic Ewing sarcoma: report of the French society of pediatric oncology.Med Pediatr Oncol. 1999; 33: 444-449
- Local therapy and other factors influencing site of relapse in patients with localised Ewing’s sarcoma. United Kingdom Children’s Cancer Study Group (UKCCSG).Eur J Cancer. 1999; 35: 1698-1704
- Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma: a report from the Cooperative Ewing’s Sarcoma Study.Cancer. 1996; 78: 892-900
- Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma.Cancer. 2007; 109: 603-611
Children’s Oncology Group. AEWS1031: A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treament of Non-Metastatic Ewing Sarcoma. https://childrensoncologygroup.org/aews1031. Accessed February 21, 2022.
- AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of IFG-1R Monoclonal Antibody Ganitumab to Multi-Agent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma.(Updated October 30, 2018)
- Ifosfamide-containing chemotherapy in Ewing’s sarcoma: the Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study.J Clin Oncol. 1998; 16: 3628-3633
- Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group.J Clin Oncol. 2012; 30: 4148-4154
- Ewing’s sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy.Int J Radiat Oncol Biol Phys. 1991; 21: 1501-1508
- Prognostic factors for local and distant control in Ewing sarcoma family of tumors.Ann Oncol. 2008; 19: 814-820
- Radiation therapy alone for sarcoma of soft tissue.Cancer. 1985; 56: 475-479
- Neoadjuvant treatment options in soft tissue sarcomas.Cancers (Basel). 2020; 12
Article info
Publication history
Published online: August 04, 2022
Accepted:
May 30,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
